November 17, 2022 – Ardigen, one of the world’s leading companies that utilizes artificial intelligence (AI) algorithms for drug discovery, is proud to announce that Mariola Fotin-Mleczek, PhD, has joined Ardigen’s Scientific Board. Her knowledge and experience will support a deeper understanding of active cancer immunotherapies in the drug discovery process provided by scientific innovation.
Mariola Fotin-Mleczek, PhD, has over 20 years of experience in developing and optimizing the broad spectrum of therapeuticals mainly based on messenger RNA (mRNA) for medical purposes. She has co-authored over 30 scientific publications with the main focus on the multiple patented mRNA-based therapies (mainly vaccines).
Mariola Fotin-Mleczek, PhD, is an internationally recognized specialist in the field of immunology and cell biology. For nearly 16 years, she worked for CureVac, the global biopharmaceutical company and took responsibility as Chief Scientific and Chief Technology Officer. Her revolutionary work has supported multiple clinical trials with cancer therapies, prophylactic vaccines, and development of antibody therapies. She is the inventor of RNActive® related key patents. In 2021, Mariola Fotin-Mleczek, PhD, was named one of the Top 25 Women Leaders in Biotechnology. For Ardigen, it is the opportune time to work even more effectively on new therapeutics in clinical development to support and guide healthcare needs in the development of medicine.
“I am excited to bring innovative science and my long-standing vision to support Ardigen’s work in drug development. I firmly believe that our joint efforts to understand cancer immunosurveillance will significantly improve Ardigen’s research strategy. I welcome the opportunity to support Ardigen on this exciting journey.” – said Mariola Fotin-Mleczek, PhD.
“I am so delighted for our Immunology team to have the opportunity to work with one of the most compelling scientists in the field, Mariola Fotin-Mleczek, PhD. We are very honored to receive her advice, scientific expertise, and her extensive knowledge of innovative new approaches, which will shape the development of our Ardigen’s technology” – comments Agnieszka Blum, MD, PhD.
Ardigen is harnessing advanced AI methods for novel precision medicine. The company accelerates therapy development by designing immunity, decoding microbiomes, analyzing biomedical images, and providing digital drug discovery services. Ardigen’s team is rooted in biology and has extensive expertise in bioinformatics, machine learning, and software engineering. The company’s in-house datasets, together with advanced AI platforms, empower the development of effective precision therapies.
More information at ardigen.com